Thus, the combination of EZH2i with other epigenetic drugs capable of disrupting the transcriptional reprogramming of cancer cells triggered by EZH2-targeted therapy may be a rational strategy to increase EZH2 inhibition effectiveness, also in advanced mCRPC. This evidence concerns the gene EZH2 and cancer.